Wall Street brokerages expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report $4.33 million in sales for the current quarter, Zacks reports. Five analysts have issued estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $2.83 million and the highest is $5.80 million. Five Prime Therapeutics reported sales of $5.77 million in the same quarter last year, which indicates a negative year over year growth rate of 25%. The business is expected to report its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full year sales of $17.37 million for the current year, with estimates ranging from $8.70 million to $26.00 million. For the next financial year, analysts forecast that the business will post sales of $51.25 million, with estimates ranging from $20.00 million to $139.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.09). Five Prime Therapeutics had a negative return on equity of 62.13% and a negative net margin of 842.84%. The business had revenue of $3.33 million during the quarter, compared to analysts’ expectations of $5.53 million.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. Wells Fargo & Co cut Five Prime Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $35.00 to $10.00 in a report on Monday, June 3rd. BidaskClub cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. ValuEngine upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Roth Capital assumed coverage on Five Prime Therapeutics in a report on Wednesday, May 29th. They issued a “neutral” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $16.00.

Several large investors have recently made changes to their positions in FPRX. Tower Research Capital LLC TRC raised its position in shares of Five Prime Therapeutics by 1,691.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,374 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 5,074 shares in the last quarter. Alambic Investment Management L.P. bought a new position in shares of Five Prime Therapeutics in the 2nd quarter worth approximately $69,000. Bailard Inc. raised its position in shares of Five Prime Therapeutics by 23.8% in the 2nd quarter. Bailard Inc. now owns 13,000 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 2,500 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Five Prime Therapeutics by 1,929.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,328 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 6,967 shares in the last quarter. Finally, Athanor Capital LP bought a new position in Five Prime Therapeutics during the 2nd quarter valued at approximately $104,000. 81.75% of the stock is owned by hedge funds and other institutional investors.

NASDAQ FPRX traded up $0.01 on Friday, hitting $5.79. The company’s stock had a trading volume of 488,200 shares, compared to its average volume of 379,125. Five Prime Therapeutics has a 52-week low of $4.89 and a 52-week high of $16.00. The company has a current ratio of 6.87, a quick ratio of 6.87 and a debt-to-equity ratio of 0.23. The company’s 50-day simple moving average is $5.56 and its 200 day simple moving average is $9.23. The firm has a market cap of $215.16 million, a P/E ratio of -1.40 and a beta of 2.58.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Recommended Story: Operating Income

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.